Head to head
Tirzepatide against Orforglipron
A weekly injection acting on two receptors against a daily pill acting on one. Convenience and mechanism point in opposite directions here, and the two have never been randomised against each other, so the comparison is between separate trial records.
Column A
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Column B
OrforglipronOrforglipron (Foundayo, oral non-peptide GLP-1 agonist)
A once-daily GLP-1 pill rather than a shot, a small molecule rather than a peptide, FDA-approved on April 1, 2026 as Foundayo for weight management.
Side by side, on the facts we can check
| Attribute | Tirzepatide | Orforglipron |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea) | FDA-approved April 1, 2026 as Foundayo for chronic weight management (boxed thyroid C-cell warning) |
| Half-life | ~5 days | ~29-49 hours |
| Molecular weight | 4,813.5 Da | ~735 Da |
| Mechanism | Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects. | Activates the GLP-1 receptor as an orally available small molecule, reducing appetite and improving glucose-dependent insulin secretion. |
| Human studies cited | 4 | 5 |
| Legal status, US | FDA-approved, prescription only | FDA-approved (Foundayo, chronic weight management), prescription only |
Frequently asked questions
What is the difference between Tirzepatide and Orforglipron?
Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists. Orforglipron: A once-daily GLP-1 pill rather than a shot, a small molecule rather than a peptide, FDA-approved on April 1, 2026 as Foundayo for weight management.
Which has stronger research evidence, Tirzepatide or Orforglipron?
This database does not grade compounds. It counts what was run in people: 4 of the 4 studies cited on the Tirzepatide profile were human work, against 5 of 5 for Orforglipron. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Tirzepatide and Orforglipron FDA-approved?
Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea). Orforglipron: FDA-approved April 1, 2026 as Foundayo for chronic weight management (boxed thyroid C-cell warning).
Related posts
Blog articles that cover Tirzepatide or Orforglipron, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.